# Body Composition and Survival in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Radiochemotherapy

**Authors:** Piotr Kolenda, Marcin Mardas, Piotr Radomyski, Maciej Trojanowski, Maria Litwiniuk, Wojciech Warchoł, Marta Stelmach-Mardas

PMC · DOI: 10.3390/nu17203309 · Nutrients · 2025-10-21

## TL;DR

This study found that lower levels of visceral and subcutaneous fat in rectal cancer patients are linked to worse survival outcomes after treatment.

## Contribution

The study introduces body composition metrics derived from CT scans as predictors of survival in rectal cancer patients undergoing neoadjuvant therapy.

## Key findings

- Low visceral adipose tissue index (VATI) was significantly associated with worse overall survival (OS).
- Low subcutaneous adipose tissue index (SATI) was also significantly linked to worse OS.
- No significant associations were found between skeletal muscle index (SMI) or physical muscle index (PMI) and survival outcomes.

## Abstract

Background: Nutritional status is a recognized determinant of treatment tolerance and clinical outcomes in oncology. This study aimed to assess body composition using computed tomography (CT) and to evaluate its association with progression-free survival (PFS) and overall survival (OS) in patients with locally advanced rectal cancer (LARC) undergoing curative multimodal therapy. Methods: A total of 216 patients with LARC who underwent neoadjuvant chemoradiotherapy (CRT) were retrospectively assessed. Two radiochemotherapy protocols were used: long-course chemoradiotherapy (lcCRT) (radiation therapy administered daily at doses of 1.8 or 2.0 Gy, for a total dose of 50.4–55.8 Gy) with concurrent chemotherapy: either 5-FU with leucovorin or capecitabine and total neoadjuvant chemoradiotherapy (tnCRT)—short-course radiotherapy (5 × 5 Gy) followed by sequential chemotherapy with CAPOX or FOLFOX. Surgery was performed 6.5 weeks after completing CRT. Radiotherapy was delivered using linear accelerators based on the Intensity-Modulated Radiation Therapy technique. CT scans were used to assess nutritional status. Survival analyses were performed. Data on food consumption frequency were collected using the Dietary Habits and Nutrition Beliefs Questionnaire (KomPAN®). Non-Healthy-Diet-Index-14 (nHDI-14) was calculated. Results: Median observation time was 58 months (range 4–118 months). VATI level and OS (HR: 0.4618 95% CI: 0.2194–0.9719, p = 0.0419), as well as SATI and OS (HR: 0.4707 95% CI: 0.2286–0.9693, p = 0.0409) were significantly associated. This association was not significant for PFS (VATI: HR: 0.7084 95% CI: 0.4055–1.2376, p = 0.2259; SATI: HR: 0.6864 95% CI: 0.3932–1.1981, p = 0.1855). SMI and PMI values were not significantly related either PFS (SMI-HR: 0.6728, 95% CI: 0.4031–1.1231, p = 0.1295; PMI-HR: 0.7385, 95% CI: 0.4628–1.1785, p = 0.2036) or OS (SMI-HR: 0.9128, 95% CI: 0.4703–1.7720, p = 0.7876; PMI-HR: 0.6592 95% CI: 0.3684–1.1794, p = 0.1603). No significant association was found between sarcopenia development and PFS (HR: 1.2733 CI: 0.7589–2.1363; p = 0.3602) or OS (HR: 1.1207; CI: 0.5681–2.2107; p = 0.7424). Significant differences between men and women in alcohol intake and nHDI-14 were observed. Conclusions: Low visceral and subcutaneous adipose tissue index were significantly associated with worse OS in patients with LARC undergoing multimodal treatment. The nHDI-14 was negatively correlated with the duration of observation and patients’ age.

## Linked entities

- **Chemicals:** 5-FU (PubChem CID 3385), leucovorin (PubChem CID 135403648), capecitabine (PubChem CID 60953), FOLFOX (PubChem CID 135659064)
- **Diseases:** rectal cancer (MONDO:0006519)

## Full-text entities

- **Diseases:** LARC (MESH:D012004), sarcopenia (MESH:D055948)
- **Chemicals:** capecitabine (MESH:D000069287), FOLFOX (MESH:C410216), leucovorin (MESH:D002955), CAPOX (-), alcohol (MESH:D000438), 5-FU (MESH:D005472)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12566768/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12566768/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12566768/full.md

---
Source: https://tomesphere.com/paper/PMC12566768